Ken Griffin Hepion Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.31 - $1.06 $817 - $2,795	-2,637 Reduced 61.54%	1,648 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.27 - $11.9 $4,664 - $205,584	-17,276 Reduced 80.13%	4,285 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $10.4 $10,996 - $224,234	21,561 New	21,561 $11,000
Q1 2022 May 16, 2022	SELL	$0.93 - $1.29 $22,011 - $30,531	-23,668 Reduced 65.52%	12,453 $16,000
Q4 2021 Feb 14, 2022	BUY	$1.14 - $1.58 $10,980 - $15,218	9,632 Added 36.36%	36,121 $41,000
Q3 2021 Nov 15, 2021	SELL	$1.39 - $2.1 $43,256 - $65,352	-31,120 Reduced 54.02%	26,489 $40,000
Q2 2021 Aug 16, 2021	BUY	$1.56 - $2.26 $47,263 - $68,471	30,297 Added 110.93%	57,609 $114,000
Q1 2021 May 17, 2021	BUY	$1.77 - $2.98 $28,732 - $48,374	16,233 Added 146.52%	27,312 $50,000
Q4 2020 Feb 16, 2021	SELL	$1.58 - $3.64 $14,588 - $33,608	-9,233 Reduced 45.46%	11,079 $24,000
Q3 2020 Nov 16, 2020	BUY	$2.84 - $4.59 $57,686 - $93,232	20,312 New	20,312 $63,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $45.7M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.